Who is sponsoring NCT03753568?

NCT03753568 is sponsored by Helsinki University Central Hospital.

What drugs are being tested in NCT03753568?

Interventions in NCT03753568: Electronic medicine reminder system.

What condition does NCT03753568 study?

NCT03753568 studies Anticoagulant Drugs, Diabetes Mellitus, Type 2.

Is NCT03753568 still recruiting?

NCT03753568 is currently status unknown. Last updated 25 March 2019.

Last reviewed 2019-03-25 · How we verify

NCT03753568

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of an Electronic Reminder System on Direct Oral Anticoagulant and Oral Diabetes Medication Adherence

Status unknown NA Last updated 25 March 2019

What this trial tests

NA trial testing Electronic medicine reminder system in Anticoagulant Drugs in 100 participants. Status unknown.

Timeline

20 March 2019

Primary endpoint
30 July 2019

1 September 2019

Quick facts

Lead sponsor	Helsinki University Central Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	20 March 2019
Primary completion	30 July 2019
Estimated completion	1 September 2019
Sites	1 location across Finland

Drugs / interventions tested

Electronic medicine reminder system

Conditions studied

Anticoagulant Drugs — all drugs for Anticoagulant Drugs →
Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Helsinki University Central Hospital

Who can join

18 and older, any sex, with Anticoagulant Drugs or Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, the effect of an electronic device attached to a push through pill package and a smart phone application on chronic disease medication adherence is studied.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Anticoagulant Drugs

Currently open trials in the same condition.

NCT06947707 — Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients · recruiting
NCT06993636 — Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years · recruiting

Other Helsinki University Central Hospital trials

Trials by the same sponsor.

NCT07423637 — The Impact of Early Automated Insulin Delivery (AID) Therapy on Diabetes Control and Comorbidities, and Cost-effectivene · NA · not yet recruiting
NCT07462559 — KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study · Phase 1 · not yet recruiting
NCT07458984 — FMT Capsules for rCDI · Phase 3 · not yet recruiting
NCT07001423 — ChOlecystectomy aFter successFul Endoscopic Common Bile Duct Stone Extraction in Elderly · NA · recruiting
NCT07155629 — Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03753568 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Helsinki University Central Hospital
Last refreshed: 25 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03753568.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing